Investment Rating - The investment rating for the company is "Accumulate" (maintained) with a current price of 3.38 CNY and a target price of 3.64 CNY over a 6-month period [1]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 350 million to 420 million CNY in 2025, representing a year-on-year growth of 50.37% to 80.44% [5][8]. - The core driver of this growth is attributed to a non-recurring investment income of 132 million CNY from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd. [8]. - The company’s main business is showing steady recovery, with a projected net profit excluding non-recurring items of 185 million to 220 million CNY, reflecting a moderate growth of 0.92% to 20.02% [8]. Summary by Sections Market Data - Total share capital is 2,232.03 million shares, with a circulation ratio of 98.46% [2]. - The highest and lowest stock prices over the past 12 months were 4.08 CNY and 2.12 CNY, respectively [2]. Performance Metrics - The company has shown relative returns of -3.81% over 1 month, 2.98% over 3 months, and 17.42% over 12 months compared to the CSI 300 index [4]. - Absolute returns were -3.70% over 1 month, 8.68% over 3 months, and 35.74% over 12 months [4]. Financial Forecast - Revenue projections for 2025-2027 are 2,252.80 million CNY, 2,392.24 million CNY, and 2,637.93 million CNY, with growth rates of -7.70%, 6.19%, and 10.27% respectively [10]. - Net profit forecasts for the same period are 352.59 million CNY, 291.40 million CNY, and 351.19 million CNY, with growth rates of 51.48%, -17.35%, and 20.52% respectively [10]. Investment Thesis - The company is positioned to benefit from a dual-track development in the pharmaceutical industry, supported by local policy incentives, which may catalyze performance growth [8]. - The product matrix covers over 300 drug registration certificates across various therapeutic areas, enhancing market penetration [8]. - The company is expected to maintain stable profitability in the existing market while expanding its pipeline and innovating in traditional Chinese medicine [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company reported a slight decline in revenue for Q1 2025, with total revenue of 1.564 billion yuan, down 5.79% year-on-year, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [6] - New orders are gradually recovering, with a significant increase in new contract amounts, exceeding 2 billion yuan in Q1 2025, representing a 20% year-on-year growth [6] - The gross margin is showing signs of recovery, with Q1 2024 gross margin at approximately 30.03%, an increase of 12.34 percentage points quarter-on-quarter [6] - The company is expected to see revenue growth from 2025 to 2027, with projected revenues of 71.11 billion, 78.79 billion, and 89.07 billion yuan, reflecting year-on-year growth rates of 7.69%, 10.80%, and 13.05% respectively [6] - The net profit attributable to shareholders is forecasted to be 1.08 billion, 1.26 billion, and 1.48 billion yuan for the years 2025 to 2027, with significant growth rates of 166.69%, 16.78%, and 17.57% respectively [6] Financial Summary - The company has a total share capital of 864.95 million shares and a market price of 44.79 yuan, resulting in a market capitalization of approximately 38.74 billion yuan [4] - The projected earnings per share (EPS) for 2025 is 1.25 yuan, with a price-to-earnings (P/E) ratio of 35.85 [4] - The return on equity (ROE) is expected to improve from 1.96% in 2024 to 6.07% in 2027 [4]

Summary of the Conference Call for Tigermed (2025 Q1) Company Overview - **Company**: Tigermed - **Industry**: Clinical Research Organization (CRO) Key Points Financial Performance - **Q1 Revenue**: Tigermed reported revenue of 1.56 billion yuan, a 20% increase quarter-on-quarter but a 5.8% decrease year-on-year [4] - **Gross Margin**: Overall gross margin was 30.03%, showing a year-on-year decline but a quarter-on-quarter improvement, primarily affected by the Clinical Trial Services (CTS) segment [2][4] - **Operating Cash Flow**: The company achieved operating cash flow of 198 million yuan, a 37.4% increase year-on-year, with a significant reduction in accounts receivable [5] - **Net New Orders**: New orders exceeded 2 billion yuan, reflecting a 20% year-on-year growth, attributed to strategic adjustments and a recovering domestic market [6] Segment Performance - **CTS Segment**: Revenue for the CTS segment was approximately 730 million yuan, down 12% year-on-year due to a decrease in new orders and a decline in average pricing [11] - **CROS Segment**: The CROS segment showed revenue growth year-on-year, with stable gross margins, indicating resilience despite challenges in the CTS segment [2][4] - **CLS Segment**: The CLS segment generated approximately 840 million yuan in revenue, with stable growth in site management services and laboratory services [12] Strategic Initiatives - **Digitalization and Automation**: Continued investment in digital and intelligent strategies, with stable management expenses despite related costs [7] - **Cost Control**: Focus on managing expenses, particularly in subsidiaries, with a notable emphasis on maintaining stable management costs [9] Market Dynamics - **Domestic Market Recovery**: The recovery of domestic orders is supported by favorable policies for innovative drugs and improved capital market conditions, expected to continue over the next 2-4 quarters [20][21] - **MNC Demand**: Multinational corporations (MNCs) are increasing their clinical research activities in China, with a notable rise in project numbers despite geopolitical uncertainties [16][18] Risks and Challenges - **Order Quality and Pricing**: The quality of new orders is expected to improve, with stable pricing observed in the domestic market, although there are concerns about the sustainability of this trend [6][19] - **Market Competition**: The CRO industry is experiencing a contraction among smaller players, which may lead to increased market share for Tigermed but also presents challenges in maintaining competitive pricing [24] Future Outlook - **Annual Goals**: The company aims for mid-double-digit growth in net new orders and over 1 billion yuan in net operating cash flow for the year [14] - **Investment Opportunities**: Continued exploration of value realization channels for innovative drug assets, with a focus on both domestic and international markets [15] Additional Insights - **Impact of Geopolitics**: Geopolitical uncertainties have had a limited impact on MNCs' R&D activities in China, as these activities are primarily driven by local market demands [18] - **Market Share Growth**: Tigermed's market share has been increasing, reflecting the overall improvement in the supply side of the CRO industry [25]